Redsense secures strong autumn with MSEK 11.2 order

Redsense Medical has received a new order valued at MSEK 11.2 from one of its U.S. distributors.

“This order will be delivered during the autumn and lays the foundation for a strong finish to 2023 for Redsense. We have been working closely with our partners to optimize inventory levels and are now working on a delivery plan. ” says Pontus Nobréus CEO of Redsense Medical.

“This large order reflects the positive development and outlook for the Redsense System in the U.S. home hemodialysis market, and we are very thankful for the trust and confidence our technology provides our customers” continues Pontus Nobréus.

This information is information that Redsense Medical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out below, on August 15 ,2023.

Contact information

For more information, please contact: 
Pontus Nobréus
CEO
Telephone: +46 72-171 1264
E-mail: pontus.nobreus (at) redsensemedical.com

Redsense Medical AB (publ), 556646-4862

ABOUT REDSENSE MEDICAL

Redsense Medical is a corporate group with operations mainly in Europe and the United States. The company has developed the Redsense System, an innovation used for monitoring and alarm in the case of blood leakage in connection with a hemodialysis treatment. Redsense Medical solves one of the most serious remaining safety problems within hemodialysis – to quickly detect Venous Needle Dislodgement and catheter leakage to minimize blood leakage. The system consists of a patented fiber optic sensor, designed for either venous needle or central venous catheter, which is connected to an alarm unit. From the very start, the development of the company's technology has been based on the demands and safety requirements of healthcare providers in the dialysis sector.